Keyphrases
Clinical Trials
100%
Drug Development
100%
Risk Outcomes
100%
Patient Outcomes
100%
Patient Benefit
100%
Risk-benefit
100%
Patient Risk
100%
Regorafenib
100%
Colorectal Cancer
28%
Overall Survival
28%
Drug Manufacturer
28%
Response Rate
14%
Complete Response
14%
PubMed
14%
Adverse Events
14%
Embase
14%
Patient Demographics
14%
Solid Tumors
14%
Continued Use
14%
Tolerability
14%
Jordan
14%
Cochrane
14%
Positive Outcomes
14%
In Cancer
14%
Progression-free Survival
14%
Drug Efficacy
14%
Trial Characteristics
14%
Oncologic
14%
Cancer Clinical Trials
14%
Objective Response Rate
14%
Cumulative Risk
14%
FDA-approved Drugs
14%
Adverse Events Profile
14%
Repurposing
14%
Solid Cancer
14%
Adverse Event Rates
14%
Median Progression-free Survival
14%
Novel Chemotherapy
14%
Objective Response
14%
RECIST Criteria
14%
Pooled Analysis
14%
New Indication
14%
Griffin
14%
Ladd's
14%
Reagan
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
100%
Regorafenib
100%
Malignant Neoplasm
57%
Adverse Event
42%
Progression Free Survival
28%
Overall Survival
28%
Colorectal Carcinoma
28%
Pharmaceutical Manufacturing
28%
Chemotherapy
14%
Tolerability
14%
Pea
14%
Solid Malignant Neoplasm
14%